Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy

  • ORIGIN Phase 2b Investigators
  • University of Leicester
  • The University of British Columbia
  • Vera Therapeutics
  • Kocaeli University
  • Rheinisch-Westfälische Technische Hochschule Aachen
  • The George Institute for Global Health India
  • Hallym University Sacred Heart Hospital
  • AZ Delta
  • The University of Sydney
  • Western Nephrology P.C.
  • Charles University
  • Stanford University

Abstract

KEY POINTS: Participants who completed a 36-week double-blind study of atacicept were eligible for a 60-week, open-label extension study. Atacicept 96-week treatment resulted in sustained reductions in galactose-deficient IgA1, hematuria, and urine protein-creatinine ratio. The slope of the eGFR was similar to that observed in the general population without kidney disease.

BACKGROUND: B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) play key roles in the pathogenesis of IgA nephropathy. Atacicept is a novel fully humanized fusion protein, self-administered at home by subcutaneous injection, that binds and inhibits BAFF and APRIL. By inhibiting BAFF and APRIL, atacicept targets the underlying B-cell–mediated pathogenesis driving disease progression. This study evaluated the long-term efficacy and safety of atacicept in patients with IgA nephropathy over 96 weeks.

METHODS: Participants with IgA nephropathy who received atacicept (25, 75, or 150 mg) or placebo in a 36-week phase 2b, randomized, blinded trial were enrolled in an open-label extension study and received atacicept 150 mg for an additional 60 weeks. Key efficacy outcomes were changes in galactose-deficient IgA1 (Gd-IgA1), percentage of participants with hematuria, urine protein-creatinine ratio (UPCR), and eGFR over 96 weeks. Long-term safety data were also evaluated.

RESULTS: There were 113 participants (67 [59%] male; 46 [41%] female) who ranged in age from 18 to 67 years who received ≥1 atacicept dose. Over 96 weeks, safety data demonstrated that atacicept was generally well tolerated. There were also sustained reductions (mean±SEM) in Gd-IgA1 (−66%±2%), percentage of participants with hematuria (−75%; 95% confidence intervals, −87 to −59; in participants with baseline hematuria), and UPCR (−52%±5%). The mean annualized slope of eGFR was −0.6±0.5 ml/min per 1.73 m2 through 96 weeks.

CONCLUSIONS: Atacicept was well tolerated over the duration of the study. Atacicept treatment reduced Gd-IgA1, hematuria, and UPCR with stabilization of eGFR through 96 weeks.

CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER:: Atacicept in Subjects with IgA Nephropathy (ORIGIN 2), NCT04716231.

PODCAST: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2024_10_26_KTS_October2024.mp3

OriginalspracheEnglisch
ZeitschriftJournal of the American Society of Nephrology
Jahrgang36
Ausgabenummer4
Seiten (von - bis)679-687
Seitenumfang9
ISSN1046-6673
DOIs
PublikationsstatusVeröffentlicht - 01.04.2025
Extern publiziertJa

Fingerprint

Untersuchen Sie die Forschungsthemen von „Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren